BrainsWay’s Deep TMS pilot study recorded an 83.3% response rate and a 50% remission rate for depressive symptoms in patients with early-stage Alzheimer’s disease. The results matter to investors because the therapy is not FDA-cleared for Alzheimer’s, and the company says controlled clinical research is required to assess the preliminary findings.

Key Highlights

  • The peer-reviewed study was published in the Journal of Geriatric Psychiatry and Neurology.
  • Researchers used BrainsWay’s H1 and H7 Coils to stimulate prefrontal and temporal brain regions.
  • Deep TMS is not FDA-cleared for treating Alzheimer’s disease, according to the release.

Deep TMS Study Records Depression Outcomes

The results included measurable changes in brain activity and connectivity. Treatment used the company’s H1 Coil on the left dorsolateral prefrontal cortex, followed by the H7 Coil on temporal regions. Researchers assessed brain activity with quantitative electroencephalography before and after treatment. The study found reduced delta-band power in the right temporal lobe, alongside increased Alpha coherence between several frontal and temporal sites.

Alzheimer’s Use Still Requires Controlled Research

Remission required a Patient Health Questionnaire-9 score of 4 or less. Deep TMS is not FDA-cleared for treating Alzheimer’s disease. BrainsWay (NASDAQ: BWAY) said the preliminary findings require further evaluation through controlled clinical research.